Blood · 2007 · 599 citations · 45 references
MedicineHematologyImmunologyHematologic OncologyStem Cell TransplantationTransplant ImmunologyDonor-recipient CompatibilityHematopoietic Stem Cell TransplantationHistocompatibilityHla MatchingNatural Killer Cell BiologyNatural Killer Cell TherapyAcute Myeloid Leukemia TherapyAcute Myeloid Leukemia TransplantationKiller-cell Immunoglobulin-like Receptor MatchingMissing-self RecognitionNatural Killer Cell AlloreactivityPositive Predictive ValuePositive Predictive Value EstimationTransplantation For Hematologic Malignancies
We analyzed 112 patients with high-risk acute myeloid leukemia (61 in complete remission [CR]; 51 in relapse), who received human leukocyte-antigen (HLA)-haploidentical transplants from natural killer (NK) alloreactive (n = 51) or non-NK alloreactive donors (n = 61). NK alloreactive donors possessed HLA class I, killer-cell immunoglobulin-like receptor (KIR) ligand(s) which were missing in the recipients, KIR gene(s) for missing self recognition on recipient targets, and alloreactive NK clones against recipient targets. Transplantation from NK-alloreactive donors was associated with a significantly lower relapse rate in patients transplanted in CR (3% versus 47%) (P > .003), better event-free survival in patients transplanted in relapse (34% versus 6%, P = .04) and in remission (67% versus 18%, P = .02), and reduced risk of relapse or death (relative risk versus non-NK-alloreactive donor, 0.48; 95% CI, 0.29-0.78; P > .001). In all patients we tested the "missing ligand" model which pools KIR ligand mismatched transplants and KIR ligand-matched transplants from donors possessing KIR(s) for which neither donor nor recipient have HLA ligand(s). Only transplantation from NK-alloreactive donors is associated with a survival advantage.
45
1994 Consensus Conference on Acute GVHD Grading.
Donna Przepiorka, Daniel Weisdorf, Peyton Martin et al. · PubMed · 1995 · 5.1K citations
Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants
Loredana Ruggeri, Marusca Capanni, Elena Urbani et al. · Science · 2002 · 3.4K citations
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Klas Kärre, Hans Ljunggren, Gerald E. Piontek et al. · Nature · 1986 · 2.1K citations
Life Sciences, Immunology, Oncology +12